CSCI — COSCIENS Biopharma Cashflow Statement
0.000.00%
- CA$13.98m
- -CA$5.53m
- $9.59m
- 23
- 55
- 37
- 32
Annual cashflow statement for COSCIENS Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -5.12 | -8.37 | -22.7 | -3.48 | -15.3 |
Depreciation | |||||
Non-Cash Items | -0.197 | -1.25 | 7.48 | -0.693 | 0.905 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.954 | 0.895 | 1.44 | 0.153 | -1.77 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -4.13 | -8.58 | -13.7 | -2.58 | -14.6 |
Capital Expenditures | — | -0.639 | -0.011 | -0.722 | -1.16 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 0.056 | -0.019 | -0.001 | -0.008 | 26.2 |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 0.056 | -0.658 | -0.012 | -0.73 | 25.1 |
Financing Cash Flow Items | -2.77 | -3.12 | 0.016 | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 20.5 | 51 | -0.118 | -0.357 | -0.588 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 16.4 | 41 | -14.7 | -3.51 | 9.71 |